Ibogaine - ATAI Life Sciences/DemeRx
Alternative Names: DMX-1002; Ibogaine HCl - ATAI Life Sciences/DemeRx; Ibogaine hydrochloride - ATAI Life Sciences/DemeRx; IBX-210Latest Information Update: 02 Apr 2024
At a glance
- Originator ATAI Life Sciences; DemeRx
- Developer ATAI Life Sciences
- Class Antipsychotics; Drug withdrawal therapies; Ethers; Heterocyclic compounds with 4 or more rings; Indoles; Neuropsychotherapeutics; Rauwolfia alkaloids; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; NMDA receptor antagonists; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Opioid-related disorders
Most Recent Events
- 28 Mar 2024 ATAI Life Sciences plans a phase I/IIa trial for Opioid related disorders in second half of 2024
- 10 Aug 2023 ATAI Life Science plans to engage regulatory authorities to assess progressing ibogaine into an efficacy study in patients with Opioid-related disorders
- 10 Aug 2023 Pharmacokinetics and adverse events data from a phase I/II trial in Opioid-related disorders released by ATAI Life Sciences